Vaccines Articles
Findings from a first in-human study for a new malaria vaccine candidate have shown a robust immune response while significantly delaying parasitemia.
Preliminary overall 2015-16 influenza vaccine effectiveness was 59 percent, according to the Centers for Disease Control and Prevention.
A new form of hybridized sound waves developed by Australian researchers may allow drugs and vaccines to be delivered to the body through a nebulizer in a fine mist inhaled into the lungs.
Two studies presented at the International Conference on Emerging Infectious Diseases show that the influenza vaccine can protect for six months, last throughout the flu season and reduce hospitalization in children.
The U.S. Food and Drug Administration(FDA) has granted exclusivity to Flublok influenza vaccine for a period of 12 years.
A new study shows that people who receive a shingles vaccine but still contract shingles have a lower risk of developing post-herpatic neuralgia (PHN).
In a first-in-people clinical trial, personalized tailor-made melanoma vaccines given to three patients with advanced melanoma appeared to increase the number and diversity of cancer-fighting T cells responding to the tumors.
At its annual meeting in June, the American Medical Association (AMA) adopted a new policy to seek more stringent state immunization requirements to allow exemptions only for medical reasons.
Three recent studies have found that interventions increase the rates of human papillomavirus (HPV) vaccination among teens and young women.
A new simulation study that evaluated the relationship between Guillain-Barré syndrome (GBS) risk and influenza vaccine and illness suggests that the vaccine reduces the risk for GBS.
Researchers investigated the role of one or more pertussis vaccinations in preventing pertussis-related deaths and risk markers for death among infants aged younger than 42 days.
According to the 2013 National HealthInterview Survey, the most recent report used by the Centers for Disease Control and Prevention (CDC), only 29.6 percent of adults ages 18 to 48 receive the flu vaccine, and that number increases to 46.5 percent for adults ages 50 to 64and 67.9 percent for adults over 68.
